---
schema_version: "secwatch.filing_event.v1"
accession: "0000313143-24-000056"
form_type: "8-K"
ticker: "HAE"
cik: "0000313143"
company_name: "HAEMONETICS CORP"
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:47:03.678629+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Haemonetics CTO Anila Lingamneni to depart on November 1, 2024

## Summary
- Anila Lingamneni, EVP and Chief Technology Officer, will leave Haemonetics effective November 1, 2024.
- No replacement for the CTO role has been announced.
- The company expressed gratitude for Ms. Lingamneni's contributions and wished her success.

## SEC filing metadata
- accession: 0000313143-24-000056
- form_type: 8-K
- ticker: HAE
- cik: 0000313143
- company_name: HAEMONETICS CORP
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/313143/000031314324000056/0000313143-24-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/313143/000031314324000056/hae-20240910.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000313143-24-000056
- JSON: https://secwatch.observer/filing/0000313143-24-000056.json
- Plain text: https://secwatch.observer/filing/0000313143-24-000056.txt

## Key facts
- Executive change
  Anila Lingamneni departed as Executive Vice President, Chief Technology Officer at HAEMONETICS CORP.
  - Action: will leave
  - Role: Executive Vice President, Chief Technology Officer
  source text: Anila Lingamneni, Executive Vice President, Chief Technology Officer, will leave Haemonetics Corporation (the “Company”) on November 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/313143/000031314324000056/0000313143-24-000056-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.